Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.42
-0.24 (-0.81%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
July 18, 2024
Pfizer Inc (NYSE: PFE) is showing a bullish Golden Cross, indicating potential upward momentum for the stock.
Via
Benzinga
Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
July 18, 2024
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said he is staying long on Pfizer Inc.
Via
Benzinga
7 Hated Stocks Set to Make a Major Comeback This Year
July 18, 2024
These seven out-of-favor stocks across various sectors have the potential to stage a significant rebound as market conditions improve.
Via
InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
July 18, 2024
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.
Via
InvestorPlace
Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
July 18, 2024
Despite their recent underperformance, these two phenomenal dividend stocks -- sporting an average yield of 5.79% -- have the recipes to make their patient shareholders notably richer.
Via
The Motley Fool
Decoding Pfizer's Options Activity: What's the Big Picture?
July 15, 2024
Via
Benzinga
Why Pfizer Stock Is Moving Higher on Thursday
July 11, 2024
Pfizer announced it will advance development of its once-daily Danuglipron.
Via
Benzinga
Current Analysis: Pfizer Inc.
July 17, 2024
Pfizer (PFE) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer’s share price rose about 20.5% from $36.32 to $30.02 as of...
Via
Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
July 17, 2024
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On...
Via
Benzinga
3 Under $50 Stocks to Buy Now: Q3 Edition
July 17, 2024
For small do-it-yourself investors looking for value, the following under $50 stocks are worth buying in July 2024.
Via
InvestorPlace
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
July 16, 2024
Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years.
Via
The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
July 16, 2024
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
July 15, 2024
Via
Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
July 13, 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector.
Via
InvestorPlace
2 Pharma Stocks to Buy Hand Over Fist This Month
July 13, 2024
These drugmakers may not be in perfect health right now, but that shouldn't last much longer.
Via
The Motley Fool
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
July 12, 2024
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector underperforms.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
July 12, 2024
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
Via
Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
July 12, 2024
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate...
Via
Benzinga
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
July 12, 2024
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.
Via
Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
July 11, 2024
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Via
Benzinga
Wall Street Weighs In As Pfizer Targets $100 Billion Weight Loss Market
July 11, 2024
Pfizer announced plans to advance a once-daily version of its weight loss pill, danuglipron, following encouraging early-stage trial results.
Via
Talk Markets
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
July 11, 2024
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Phase 1 pharmacokinetic study results. Dose optimization studies will follow...
Via
Benzinga
Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug
July 11, 2024
The company now plans to run multiple tests of the drug, danuglipron, to determine the right dose for registration-enabling studies.
Via
Investor's Business Daily
Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone
July 11, 2024
Several stocks angled higher early Thursday with one in a buy zone and two looking to reclaim key levels.
Via
Investor's Business Daily
7 High-Yield Dividend Stocks to Buy and Hold Forever: July Edition
July 11, 2024
Explore the top seven high-yield dividend stocks, leading in several industries to buy and hold for income stability.
Via
InvestorPlace
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
July 11, 2024
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks.
Via
InvestorPlace
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
July 10, 2024
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside.
Via
InvestorPlace
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
July 10, 2024
This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V.
Via
Benzinga
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
July 10, 2024
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.